S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

TransMedics Group Stock Forecast, Price & News

-0.95 (-4.20%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
246,284 shs
Average Volume
459,814 shs
Market Capitalization
$601.18 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TMDX News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TransMedics Group logo

About TransMedics Group

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.


TransMedics (TMDX) Reports Q3 Loss, Lags Revenue Estimates
November 10, 2021 |  finance.yahoo.com
TransMedics Reports Third Quarter 2021 Financial Results
November 9, 2021 |  finance.yahoo.com
TransMedics Reports Positive Data From OCS DCD Heart Trial
November 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Electromedical equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$25.64 million
Book Value
$2.83 per share


Net Income
$-28.75 million
Net Margins
Pretax Margin




Free Float
Market Cap
$601.18 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.42 out of 5 stars

Medical Sector

178th out of 1,390 stocks

Electromedical Equipment Industry

4th out of 30 stocks

Analyst Opinion: 3.3Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions

Is TransMedics Group a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TransMedics Group stock.
View analyst ratings for TransMedics Group
or view top-rated stocks.

How has TransMedics Group's stock been impacted by Coronavirus?

TransMedics Group's stock was trading at $13.62 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TMDX stock has increased by 59.0% and is now trading at $21.65.
View which stocks have been most impacted by COVID-19

Are investors shorting TransMedics Group?

TransMedics Group saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,330,000 shares, an increase of 50.1% from the October 31st total of 886,200 shares. Based on an average trading volume of 224,500 shares, the days-to-cover ratio is presently 5.9 days. Currently, 5.4% of the shares of the company are short sold.
View TransMedics Group's Short Interest

When is TransMedics Group's next earnings date?

TransMedics Group is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for TransMedics Group

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) announced its earnings results on Tuesday, November, 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.15. TransMedics Group had a negative net margin of 134.15% and a negative trailing twelve-month return on equity of 41.03%. During the same period in the prior year, the company earned ($0.19) earnings per share.
View TransMedics Group's earnings history

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $27.60 million-$28.60 million, compared to the consensus revenue estimate of $33.01 million.

What price target have analysts set for TMDX?

5 equities research analysts have issued 1 year price targets for TransMedics Group's stock. Their forecasts range from $30.00 to $79.00. On average, they anticipate TransMedics Group's stock price to reach $46.40 in the next twelve months. This suggests a possible upside of 114.3% from the stock's current price.
View analysts' price targets for TransMedics Group
or view top-rated stocks among Wall Street analysts.

Who are TransMedics Group's key executives?

TransMedics Group's management team includes the following people:
  • Waleed H. Hassanein, President, Chief Executive Officer & Director
  • John F. Carey, Vice President-Operations (LinkedIn Profile)
  • Stephen Gordon, Chief Financial Officer, Secretary & Treasurer (LinkedIn Profile)
  • Mark Anderson, Senior Director-Technology Development
  • John Sullivan, Vice President-Quality & Engineering

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group CEO Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among TransMedics Group's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.69%), Macquarie Group Ltd. (5.88%), Credit Suisse AG (5.49%), Bellevue Group AG (2.10%), Geode Capital Management LLC (1.58%) and Dimensional Fund Advisors LP (1.36%). Company insiders that own TransMedics Group stock include Abrams Capital Management, LP, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends for TransMedics Group

Which major investors are selling TransMedics Group stock?

TMDX stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Two Sigma Investments LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Dimensional Fund Advisors LP, Voloridge Investment Management LLC, Citadel Advisors LLC, and Goldman Sachs Group Inc.. Company insiders that have sold TransMedics Group company stock in the last year include Abrams Capital Management, LP, James R Tobin, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, and Waleed H Hassanein.
View insider buying and selling activity for TransMedics Group
or view top insider-selling stocks.

Which major investors are buying TransMedics Group stock?

TMDX stock was bought by a variety of institutional investors in the last quarter, including Next Century Growth Investors LLC, Moody Aldrich Partners LLC, Calamos Advisors LLC, Macquarie Group Ltd., Morgan Stanley, Russell Investments Group Ltd., US Bancorp DE, and Hsbc Holdings PLC.
View insider buying and selling activity for TransMedics Group
or or view top insider-buying stocks.

How do I buy shares of TransMedics Group?

Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $21.65.

How much money does TransMedics Group make?

TransMedics Group has a market capitalization of $601.18 million and generates $25.64 million in revenue each year. The company earns $-28.75 million in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does TransMedics Group have?

TransMedics Group employs 110 workers across the globe.

What is TransMedics Group's official website?

The official website for TransMedics Group is www.transmedics.com.

Where are TransMedics Group's headquarters?

TransMedics Group is headquartered at 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The company can be reached via phone at (978) 552-0900 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.